Evidence map›Paper›PMID 33015528›Full record

ArticleJCO precision oncology2020

Undetectable

Mohamed Bouchahda, Raphael Saffroy, Abdoulaye Karaboué, Jocelyne Hamelin, Pasquale Innominato, Faouzi Saliba, Francis Lévi, Nelly Bosselut, Antoinette Lemoine

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Current Status of Precision Medicine in Colorectal Cancer in Japan.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Anti-epidermal growth factor receptor treatment for patients with NeoTherapeutic advances in medical oncology · 2023
    Article
  12. Article
  13. Cancers · 2022
    Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 2 countries.

Mohamed BouchahdaMedical Oncology Department, Paul Brousse Hospital, Villejuif, France.
Raphael SaffroyOncogenetics Department, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Université Paris-Saclay, Villejuif, France.
Abdoulaye KarabouéFrench National Institute for Health and Medical Research (INSERM), Unit 935, Villejuif, France.
Jocelyne HamelinOncogenetics Department, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Université Paris-Saclay, Villejuif, France.
Pasquale InnominatoFrench National Institute for Health and Medical Research (INSERM), Unit 935, Villejuif, France.
Faouzi SalibaCentre Hépato Biliaire, Assistance Publique-Hôpitaux de Paris, Hôpital Paul Brousse, Villejuif, France.
Francis LéviMedical Oncology Department, Paul Brousse Hospital, Villejuif, France.
Nelly BosselutOncogenetics Department, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Université Paris-Saclay, Villejuif, France.
Antoinette LemoineOncogenetics Department, Assistance Publique-Hôpitaux de Paris, Paul Brousse Hospital, Université Paris-Saclay, Villejuif, France.
Hôpital Paul-Brousse · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRBetsi Cadwaladr University Health Board · GBGroupe Hospitalier Intercommunal Le Raincy Montfermeil · FRInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeCombining cetuximab with chemotherapy provides clinical benefit to 60% of the patients with MATERIALS AND

methodsThe occurrence of Kirsten rat sarcoma viral oncogene homolog (

resultsOf 16 registered patients, 11 were male and five female. They were age 48 to 81 years, and they had unresectable metastatic adenocarcinoma from the colon (n = 11) or rectum (n = 5), with a median of two metastatic sites. They had received a median number of three previous chemotherapy protocols. Plasma genotyping identified

conclusionPatients with

Identifiers

PMID33015528
PMCPMC7529530
OpenAlexW3087510420

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.